Paper · 42618642
Exploring the landscape of targetable alterations in patients with glioblastoma.
Aquilanti E and 10 others. Nat Rev Clin Oncol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Exploring the landscape of targetable alterations in patients with glioblastoma. Papers, record 42618642. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42618642
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| Brain Neoplasms | Major topic |
| Molecular Targeted Therapy | Major topic |
| Antineoplastic Agents | Major topic |
| Humans |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References269
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39,387,386 | Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1. | Neuro Oncol | 2025 | https://conductscience.org/library/papers/39387386 | PubMed |
| 2 | 27,306,666 | Clinical trial of blood-brain barrier disruption by pulsed ultrasound. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/27306666 | PubMed |
| 3 | 36,990,614 | Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36990614 | PubMed |
| 4 | 37,059,069 | Cancer neuroscience: State of the field, emerging directions. | Cell | 2023 | https://conductscience.org/library/papers/37059069 | PubMed |
| 5 | 23,348,506 | Highly recurrent TERT promoter mutations in human melanoma. | Science | 2013 | https://conductscience.org/library/papers/23348506 | PubMed |
| 6 | 38,008,230 | Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment. | Biochim Biophys Acta Mol Basis Dis | 2024 | https://conductscience.org/library/papers/38008230 | PubMed |
| 7 | 15,210,860 | SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. | Mol Cancer Ther | 2004 | https://conductscience.org/library/papers/15210860 | PubMed |
| 8 | 38,079,020 | "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. | Acta Neuropathol | 2023 | https://conductscience.org/library/papers/38079020 | PubMed |
| 9 | 38,181,810 | PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/38181810 | PubMed |
| 10 | 22,837,387 | Transforming fusions of FGFR and TACC genes in human glioblastoma. | Science | 2012 | https://conductscience.org/library/papers/22837387 | PubMed |
1 to 10 of 269
See all 269 referencesCited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,942,833 | From Target Discovery to Spatial Delivery: A Translational Roadmap for Gene-Targeted Therapies in Glioma. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942833 |
Source PubMed
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42618642
GET https://conductscience.org/api/papers/v1/42618642/references?page=2